Cost-Effectiveness of Universal or High-Risk Screening Compared to Surveillance Monitoring in Autism Spectrum Disorder

The American Academy of Pediatrics recommends universal screening for autism spectrum disorder at 18 and 24 months. This study compared the cost-effectiveness of universal or high-risk screening to surveillance monitoring. Simulation models estimated the costs and outcomes from birth to age 6 years....

Full description

Saved in:
Bibliographic Details
Published in:Journal of autism and developmental disorders 2018-09, Vol.48 (9), p.2968-2979
Main Authors: Yuen, Tracy, Carter, Melissa T., Szatmari, Peter, Ungar, Wendy J.
Format: Article
Language:English
Subjects:
At Risk Persons
Autism
Autism Spectrum Disorder - diagnosis
Autism Spectrum Disorder - economics
Autism Spectrum Disorder - epidemiology
Autistic children
Behavioral Science and Psychology
Care and treatment
Child
Child and School Psychology
Child, Preschool
Childbirth & labor
Children
Clinical Diagnosis
Comparative Analysis
Cost analysis
Cost benefit analysis
Cost control
Cost Effectiveness
Cost-Benefit Analysis - methods
Diagnosis
Economic aspects
Female
Health screening
High risk
Humans
Infant
Male
Mass Screening - economics
Mass Screening - methods
Medical screening
Neurosciences
Original Paper
Patient outcomes
Pediatrics
Pervasive Developmental Disorders
Psychology
Public Health
Risk Factors
Savings
Screening Tests
Simulation
Surveillance
United States - epidemiology
Waiting times
Young Children
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The American Academy of Pediatrics recommends universal screening for autism spectrum disorder at 18 and 24 months. This study compared the cost-effectiveness of universal or high-risk screening to surveillance monitoring. Simulation models estimated the costs and outcomes from birth to age 6 years. The incremental cost per child diagnosed by 36 months was $41,651.6 for high-risk screening and $757,116.9 for universal screening from the societal perspective. Universal screening may not be a cost-effective approach to increase earlier treatment initiation, as most children initiated treatment after age 60 months. Eliminating wait times resulted in more children initiated treatment by 48 months, but at a high initial cost that may be offset by future cost-savings related to better outcomes.
ISSN:0162-3257
1573-3432
DOI:10.1007/s10803-018-3571-4